[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Urogen Pharma Ltd (URGN)

Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Urogen Pharma Ltd 400 Alexander Park Drive Princeton NJ 08540 USA

www.urogen.com Employees: 291 P: 646-768-9780

Sector:

Medical

Description:

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel.

Key Statistics

Overview:

Market Capitalization, $K 2,224,086
Enterprise Value, $K 2,234,196
Shares Outstanding, K 48,881
Float, K 46,535
% Float 95.20%
Short Interest, K 4,589
Short Float 9.39%
Days to Cover 6.64
Short Volume Ratio 0.64
% of Insider Shareholders 4.80%
% of Institutional Shareholders 91.29%

Financials:

Annual Sales, $ 109,790 K
Annual Net Income, $ -153,490 K
Last Quarter Sales, $ 72,460 K
Last Quarter Net Income, $ -14,350 K
EBIT, $ -66,660 K
EBITDA, $ -68,230 K

Growth:

1-Year Return 126.72%
3-Year Return 150.83%
5-Year Return 153.91%
5-Year Revenue Growth 830.42%
5-Year Earnings Growth 45.93%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.28 on 08/05/26
Next Earnings Date 11/05/26
Earnings Per Share ttm -1.98
EPS Growth vs. Prev Qtr 40.43%
EPS Growth vs. Prev Year 73.33%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

URGN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -43.79%
Profit Margin % -139.80%
Debt/Equity -1.43
Price/Sales 20.45
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -2.71
Interest Coverage -8.99
60-Month Beta 1.57
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.